Equillium reports itolizumab Phase 2 UC topline: 23.3% clinical remission vs 10% placebo

Equillium, Inc.

Primary endpoint: 23.3% clinical remission at week 12 for itolizumab vs 20.0% adalimumab, 10.0% placebo.
Secondary: 63.3% clinical response (itolizumab) vs 60.0% adalimumab, 46.7% placebo; endoscopic remission 16.7% each itolizumab/adalimumab vs 6.7% placebo.
Baseline imbalance: 23% of itolizumab arm had severe disease (Mayo=11) vs 0% placebo/adalimumab; 66% left-sided colitis vs 30%/43%.
Itolizumab was generally well tolerated with no new safety signal; 90 patients randomized 1:1:1 in India.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.